Navigation Links
Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Date:11/12/2007

/p>

Senior Director, Corporate Communications

Trubion Pharmaceuticals Inc.

(206) 838-0500

jdenike@trubion.com

Waggener Edstrom Healthcare

Jenny Moede

Senior Vice President

(503) 443-7000

jmoede@wagged.com

-FINANCIAL TABLES FOLLOW-

TRUBION PHARMACEUTICALS. INC.

STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(unaudited)

Three months ended Nine months ended

September 30, September 30,

2007 2006 2007 2006

Revenue $4,635 $16,539 $14,450 $30,175

Operating expenses:

Research and development 8,877 9,570 28,201 23,451

General and administrative 2,578 2,032 7,652 7,101

Total operating expenses 11,455 11,602 35,853 30,552

Income (loss) from operations (6,820) 4,937 (21,403) (377)

Interest income 1,120 419 3,582 1,389

Interest expense (213) (49) (566) (163)

Other income - 83 - 22

Net income (loss) $(5,913) $5,390 $(18,387) $871

Basic net income (loss) per share $(0.33) $3.79 $(1.04) $0.63

Diluted net income (loss) per share $(0.33) $0.40 $(1.04) $0.06

Shares used in computation of basic

net income (loss) per share 17,758 1,421 17,654 1,376

Shares used in computation of diluted

net income (loss) per share 17,758 13,245
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/8/2008)...ieve undetectable HCV RNA levels, following 4 week...R) plus Copegus(R) -,...dministered with Pegasys ...wswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: VR...th cohort of a,4-week Phase 1 proof-of-concept cli...
(Date:9/8/2008)...ement Consulting announced that it has appointed A... Charlotte, NC (PRWEB) September 8, 2008...ment Consulting] announced that it has appointed A...len joins Symphony from Wellesley Information Serv... developing, and producing national educational co...
(Date:9/6/2008)...elps visitors to electronica 2008 in Munich and co...ctronica information available on the visitor hotl...nning a trip, online registration benefits, a summ...ludes an extensive list of web links to travel, ho... Munich, Germany (PRWEB) September 6, 2008 -...
(Date:9/5/2008)...stitute of Standards and Technology (NIST) and Seo...weak a new class of polymer-based semiconductors t... components of the blend. Their recent resultshow ...gn of practical, large-scale manufacturing techniq...onic displays and other devices.* , Organic semi...
Breaking Biology Technology:Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6Symphony Managemnt Consulting Hires New Solutions Director 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 3Bottoms up: Better organic semiconductors for printable electronics 2
...Neurognostics, Inc. , a Wisconsin company speciali...I) products and services, has been honored with a ...tanding Achievements. , ,Last year Neurognostics r...ch (SBIR) Grant from the National Institutes of He...RI-based biomarkers in Parkinson,s disease. Neurog...
... GE Healthcare,s LightSpeed VCT, the world,s firs...gnized today by the Wall Street Journal in the M... Technology Innovation Awards. The annual awards r...s, companies and organizations around the world in...e Wall Street Journal received approximately 750 a...
...rent Energy Systems, Inc. announced today that Dr...Dr. Raman is President of Protium Energy Technolo...gen, fuel cells and alternative energy, based in A..., Inc., is developing Aqueous Phase Reforming (APR...fuel gases and other high value chemicals. APR us...
... Wis.— Renaissance Learning , Inc., a provi...ring tools for pre-K-12 schools and districts, wil...raining and certification office center for all Re...also plans to adjust space needs at other faciliti...s Wisconsin Rapids operation. , ,As part of its Al...
Other Biology Technology:
(Date:9/8/2008)...lif., September 8, 2008For allergy sufferers, the ...without pets or curtains or anything that could tr... extends its Anywhere® product line with the l...abric Spray, a new product to help manage indoor a...rox® Anywhere® Anti-Allergen Fabric Spray ...
(Date:9/8/2008)..., September 2, 2008 -- A new interactive web lesso...raduate students how herbicides are developed. The...te University, has the seal of approval by the Jo...tion and is published in the 2008 issue. , Surp...et today were discovered by random searching. Coll...
(Date:9/7/2008)...s ability to sweat may do more than keep the body ...ise-induced asthma (EIA), a common respiratory con...ing in the September issue of CHEST, the peer-re...ysicians (ACCP), shows that athletes with EIA prod...o not have breathing problems. , Warren Lockett...
(Date:9/7/2008)...A Even closely related plants produce their own n...ed to the individual plant,s specific habitat. Com...e, researchers at the Salk Institute for Biologica...a key enzyme are enough to shift the whole output ...hanges led to a mixture of henbane and tobacco-spe...
Breaking Biology News(10 mins):The Clorox Company's new indoor allergen product reduces common indoor allergens up to 90 percent 2Athletes' 'sweat and tears' linked to asthma 2Athletes' 'sweat and tears' linked to asthma 3How plants fine tune their natural chemical defenses 2How plants fine tune their natural chemical defenses 3Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 1Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 2Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 3Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 4Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 5Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 6Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4161 7Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients 1587 1Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients 1587 2Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients 1587 3VaxGen Issues Rebuttal to MedCap Letter 4156 1VaxGen Issues Rebuttal to MedCap Letter 4156 2VaxGen Issues Rebuttal to MedCap Letter 4156 3VaxGen Issues Rebuttal to MedCap Letter 4156 4VaxGen Issues Rebuttal to MedCap Letter 4156 5VaxGen Issues Rebuttal to MedCap Letter 4156 6VaxGen Issues Rebuttal to MedCap Letter 4156 7VaxGen Issues Rebuttal to MedCap Letter 4156 8VaxGen Issues Rebuttal to MedCap Letter 4156 9VaxGen Issues Rebuttal to MedCap Letter 4156 10VaxGen Issues Rebuttal to MedCap Letter 4156 11Tempo Participacoes S A Announces Increase of 16 8 25 in Net Revenue and of 46 3 25 in EBITDA for 2007 15024 1
... be frighteningly large if only there was a greate...concludes. The study adds support to the theory th...aleozoic period because they had a much richer oxy... Kaiser. , The study, "No giants today: tracheal o...l be presented Oct. 10 and 11 at Comparative Physi...
...rve pain ?by aiming drugs at a previously unrecogn...ersity of Utah scientists who study the venoms of ...new way to treat a chronic and debilitating form o...on Earth," says J. Michael McIntosh, a University ...h director and professor in the Department of Psyc...
...ohn Shelnutt and Yujiang Song have discovered a be...rough a new process that produces novel hollow pla...s a paper in an upcoming issue of the German chemi...of publication, it is featured as a short "hot pap...ional Nuclear Security Administration laboratory. ...
...ans diverged from a common ancestor and evolved in...ified a new way to pinpoint the genes that separat... uniquely human. The Proceedings of the National ...13 online edition. , "We share more than 95 perc...ed Dr. Daniel Geschwind, principal investigator an...
Other Biology News:Giant insects might reign if only there was more oxygen in the air 2Giant insects might reign if only there was more oxygen in the air 3A new target for painkillers 2A new target for painkillers 3A new target for painkillers 4Sandia researchers discover way to see how a drug attaches to a cell 2Unraveling where chimp and human brains diverge 2
...it Polyclonal to Human CELSR3 CELSR3 is an Orpha...ene is expressed during development at sites of ac...ain, spinal cord, dorsal root ganglion, and eye. E...is, blood, brain, colon, heart/melanocyte/uterus, ...
...ination inline heater plus multi-channel focal dru...ug wash-out with a high-flow bath line while quick...e Perfusion Pencil.® Steady 37°C at 5 ml/...ip. Advanced auto-tuning temperature lock Desig...
Immunogen: purified recombinant human angiogenin expressed in E. coli . Physical form: Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline. Titertest method: ELISA (c).
CKB Antibody (N-term) Antigen: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected within aa 1~100 of human CKB. Molecular Weight: 42644 Da
Biology Products: